



July 15, 2019

Dear Members of the Angelman Community,

Firstly, on behalf of all of us at Ovid, I want to thank you for the continued support. Your messages inspire us, and the pictures you send hang on our walls as a constant reminder of what matters most. Please keep the messages and pictures coming!

Secondly, and importantly, an exciting update on our NEPTUNE phase 3 clinical trial and information for those families considering participation. We want to clarify the next steps and provide details including site locations, approximate dates and contact information.

- 1) *Locations*: NEPTUNE study sites in the United States will be located in Pennsylvania, Arizona, North Carolina, Massachusetts, Washington and Illinois. International study sites will be located in Israel, Australia, Italy and the Netherlands. More study locations may be added and announced later in the year.
- 2) The website dedicated to this study is: www.angelmanstudy.com. This website will go live on August 1st. On this website, there will be a link to a pre-screener which will help determine eligibility. This website will also have detailed updates about the NEPTUNE phase 3 clinical trial.
- 3) *Ages*: Enrollment for NEPTUNE is staggered by age. This means the first participants (able to enroll in **August**) will be between the ages of 9-12. The second age group (**beginning November/December**) will be ages 4-8. The third age group (**beginning January/February 2020**) will be ages 2-3.
- 4) To inquire about participation in the NEPTUNE phase 3 clinical trial, email: AngelmanStudy@ovidrx.com.

Please reach out with any questions!

Sincerely,

Luke Rosen

Luke Rosen
Vice President, Patient Engagement &
Government Affairs
Ovid Therapeutics